Spray-dried metal-organic frameworks for treatment and/or diagnosis of pulmonary disease

Patent metadata

Field	Value
Publication number	US-2023398112-A1
Application number	US-202118020687-A
Country	US
Kind code	A1
Filing date	Jul 30, 2021
Priority date	Aug 10, 2020
Publication date	Dec 14, 2023
Grant date	—

Abstract

Spray-dried metal-organic frameworks (MOFs) comprising therapeutic and/or diagnostic metal ions and therapeutic and/or diagnostic organic ligands are described. Both the metal ion and organic ligand can have activity related to the treatment and/or diagnosis of a pulmonary disease or disorder, such as tuberculosis, or another disease related to a pulmonary infection. The MOFs can be adminstered to subjects via inhalation (e.g., as aerosols). Methods of treating and diagnosing pulmonary diseases or disorders are also described.

First claim

What is claimed is:

1 . A spray-dried metal-organic framework (MOF) particle for treating and/or detecting a pulmonary disease or disorder, the spray-dried MOF particle comprising:
a metal ion, optionally wherein the metal ion is an ion of an element selected from an alkaline metal, an alkaline earth metal, a transition metal, and a lanthanide; and an organic ligand coordinated to said metal ion, wherein said organic ligand comprises at least two metal coordination sites and wherein the organic ligand has a biological activity related to treatment of the pulmonary disease or disorder, is a prodrug of a therapeutic agent that has a biological activity related to treatment of the pulmonary disease or disorder, and/or has a property useful for biomedical imaging.

2 . The spray-dried MOF particle of claim 1 , wherein the metal ion has a biological activity related to treatment of the pulmonary disease or disorder and/or a property useful for biomedical imaging, optionally wherein the metal ion is an ion of a transition metal or a lanthanide.

3 . The spray-dried MOF particle of claim 2 , wherein the metal ion is an ion of an element selected from the group consisting of copper (Cu), iron (Fe), palladium (Pd), zinc (Zn), silver (Ag), gold (Au), manganese (Mn), cobalt (Co), rhodium (Rh), nickel (Ni), tantalum (Ta), titanium (Ti), tungsten (W), yttrium (Y), vanadium (V), platinum (Pt), gadolinium (Gd), and ytterbium (Yb).

4 . The spray-dried MOF particle of any one of claims 1 - 3 , wherein the organic ligand is a therapeutic agent selected from an anti-asthmatic, an antihistamine, a antitussive, a bronchodilator, a decongestant, an expectorant, a leukotriene modifier, a lung surfactant, an anti-infective, a corticosteroid, a mast cell stabilizer, a mucolytic, a selective phosphodiesterase-4 inhibitor, or a combination or prodrug thereof.

5 . The spray-dried MOF particle of any one of claims 1 - 4 , wherein the spray-dried MOF particle has an average particle diameter of between about 1 μm and about m, optionally between about 2 μm and about 3 μm.

6 . The spray-dried MOF particle of any one of claims 1 - 5 , wherein the spray-dried MOF particle is hollow.

7 . The spray-dried MOF particle of any one of claims 1 - 6 , wherein the organic ligand comprises pyrazinoic acid.

8 . The spray-dried MOF particle of any one of claims 1 - 7 , wherein the spray-dried MOF particle comprises bis(pyrazine-2-carboxylato)copper(II) (Cu(POA) 2 ), optionally wherein said Cu(POA) 2 is hydrated or solvated.

9 . The spray-dried MOF particle of any one of claims 1 - 7 , wherein the spray-dried MOF particle comprises at least two different metal ions.

10 . The spray-dried MOF particle of any one of claims 1 - 7 , wherein the spray-dried MOF particle comprises at least two different organic ligands, optionally wherein each of the at least two different organic ligands are selected from the group consisting of an anti-asthmatic, an antihistamine, a antitussive, a bronchodilator, a decongestant, an expectorant, a leukotriene modifier, a lung surfactant, an anti-infective, a corticosteroid, a mast cell stabilizer, a mucolytic, a selective phosphodiesterase-4 inhibitor, and a combination thereof.

11 . A therapeutic and/or diagnostic composition, the composition comprising an aerosolized form of a spray-dried MOF particle of claim 1 with an aerodynamic particle size distribution (APSD) in a range suitable for pulmonary delivery, optionally about 1-5 microns.

12 . The therapeutic and/or diagnostic composition of claim 11 , further comprising an excipient or carrier selected from the group consisting of a sugar, a peptide, a lipid and a surfactant.

13 . The therapeutic and/or diagnostic composition of claim 11 or claim 12 , wherein the spray-dried MOF comprises at least one metal ion of an element selected from a transition metal and a lanthanide, optionally at least one metal ion of an element selected from copper (Cu), iron (Fe), palladium (Pd), zinc (Zn), silver (Ag), gold (Au), manganese (Mn), cobalt (Co), rhodium (Rh), nickel (Ni), tantalum (Ta), titanium (Ti), tungsten (W), yttrium (Y), vanadium (V), platinum (Pt), gadolinium (Gd), and ytterbium (Yb).

14 . The therapeutic and/or diagnostic composition of any one of claims 11 - 13 , wherein the spray-dried MOF comprises at least one ligand comprising at least two metal coordination sites and selected from the group consisting of an anti-asthmatic, an antihistamine, a antitussive, a bronchodilator, a decongestant, an expectorant, a leukotriene modifier, a lung surfactant, an anti-infective, a corticosteroid, a mast cell stabilizer, a mucolytic, a selective phosphodiesterase-4 inhibitor, and a combination thereof.

15 . The therapeutic and/or diagnostic composition of any one of claims 11 - 14 , wherein the composition is configured to treat and/or diagnose a pulmonary disease or disorder when administered by inhalation, wherein the pulmonary disease or disorder is selected from a bacterial infection, a viral infection, asthma, chronic obstructive pulmonary disorder (COPD), cystic fibrosis, emphysema, bronchitis, pneumonia, lung cancer and any other disease or disorder treatable using an anti-asthmatic, an antihistamine, an antitussive, a bronchodilator, a decongestant, an expectorant, a leukotriene modifier, a lung surfactant, a corticosteroid, a mast cell stabilizer, a mucolytic, or a selective phosphodiesterase-4 inhibitor.

16 . The therapeutic and/or diagnostic composition of claim 15 , wherein the therapeutic and/or diagnostic composition is configured to treat tuberculosis (TB) when administered by inhalation.

17 . The therapeutic and/or diagnostic composition of any one of claims 11 - 16 , wherein the spray-dried MOF particle comprises bis(pyrazine-2-carboxylato)copper(II) (Cu(POA) 2 ).

18 . The therapeutic and/or diagnostic composition of any one of claims 11 - 17 , wherein the aerosolized formulation of the spray-dried MOF particle comprises an APSD of about 2-3 microns (m).

19 . The therapeutic and/or diagnostic composition of any one of claims 11 - 18 , wherein the composition comprises a sugar excipient or carrier, wherein the sugar is selected from maltodextrin, mannitol, trehalose, lactose, and/or dextrose.

20 . The therapeutic and/or diagnostic composition of any one of claims 11 - 19 , wherein the composition comprises a peptide excipient or carrier, wherein said peptide is one or more of leucine, lysine, glycine, polyleucine (dileucine, trileucine), and/or polylysine (dilysine).

21 . A method of treating a pulmonary disease or disorder in a subject, the method comprising:
providing a subject in need of treatment; providing an inhalable formulation of a spray-dried MOF particle of claim 1 , wherein at least one of the metal ion and the organic ligand has a biological activity related to treatment of the pulmonary disease or disorder; and administering an effective amount of the inhalable formulation of the spray-dried MOF particle to the subject by inhalation, wherein the pulmonary disease or disorder in the subject is treated.

22 . The method of claim 21 , wherein the inhalable formulation of the spray-dried MOF particle comprises an aerosolized form of the spray-dried MOF particle having an aerodynamic particle size distribution (APSD) in a range suitable for pulmonary delivery, optionally 1-5 μm, further optionally 2-3 μm.

23 . The method of claim 21 or claim 22 , wherein the spray-dried

Assignees

• Res Triangle Inst

Inventors

• Stewart Ian Edward
• Minguez Ignacio Luz
• Hickey Anthony James

Classifications

• A61K31/4965 Primary

  Non-condensed pyrazines · CPC title

• A61K9/1611

  Inorganic compounds · CPC title

• A61K9/0073

  Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M) · CPC title

• A61K49/1887

  Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same maxtrix · CPC title

• A61K49/0419

  Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer · CPC title